News und Analysen
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
Kaufman & Broad SA: Press release of the 2025, July 25
Kaufman & Broad SA: Press release of the 2025, July 25
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Prodware: 15.4% Increase in Revenue in the First Half of 2025
Prodware: 15.4% Increase in Revenue in the First Half of 2025
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: Abivax Announces Launch of Public Offering
Kaufman & Broad SA: AVAILABILITY OF THE 2025 HALF YEARLY INTERIM FINANCIAL REPORT
Kaufman & Broad SA: AVAILABILITY OF THE 2025 HALF YEARLY INTERIM FINANCIAL REPORT
BILENDI: Revenue for the first half of 2025: €43.5 million, up +42.2%
BILENDI: Revenue for the first half of 2025: €43.5 million, up +42.2%
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
Half-year results 2025 of Sartorius Stedim Biotech
Half-year results 2025 of Sartorius Stedim Biotech
Kaufman & Broad SA: IMPLEMENTATION OF THE SHARE BUY-BACK PROGRAM
Kaufman & Broad SA: IMPLEMENTATION OF THE SHARE BUY-BACK PROGRAM
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
FIGEAC AÉRO: FIGEAC AÉRO ANNOUNCES INITIATION OF STOCK COVERAGE BY CIC MARKET SOLUTIONS
FIGEAC AÉRO: FIGEAC AÉRO ANNOUNCES INITIATION OF STOCK COVERAGE BY CIC MARKET SOLUTIONS
FIGEAC AÉRO: MTI DRIVES FURTHER GROWTH IN THE HYDROPOWER MARKET
FIGEAC AÉRO: MTI DRIVES FURTHER GROWTH IN THE HYDROPOWER MARKET
GenSight Biologics Reports Cash Position as of June 30, 2025
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA 2025, June 30
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA 2025, June 30
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech